The breast carcinomas immunophenotype is determined by using biomarkers such as estrogen receptor (ER), progesterone receptor (PR), human epidermal growth factor 2 (HER2) and Ki-67 proliferation marker, which constitute prognostic factors and are important predictive factors for hormonal and anti-HER2-targeted therapy [156]. Here, MKI67 is linked to breast carcinoma.